^
    Back
    Association details:
    Biomarker:CXCL13 mutation + ARID1A mutation
    Cancer:Urothelial Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GU 2021
    Title:

    Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer.

    Published date:
    02/08/2021
    Excerpt:
    We then interrogated CXCL13 expression plus ARID1A mutation as a combination biomarker in predicting response to immune checkpoint therapy in CheckMate275 and IMvigor210. Combination of the 2 biomarkers in baseline tumor tissues showed improved OS compared to either single biomarker.
    DOI:
    10.1200/JCO.2021.39.6_suppl.488